What do systematic reviews say?

SGLT2 inhibitors vs placebo

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney failure median compared with placebo (high certainty).

• Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes only
  RR 0.7 [0.62, 0.79]
  6 studies · 11232 participants
  High